Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19.
Saved in:
| Title: | Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19. |
|---|---|
| Authors: | Robinson P; Infectious Disease, Hoag Memorial Hospital Presbyterian, Newport Beach, California, USA., Toussi SS; Pfizer Worldwide Research, Development and Medical, Pfizer Inc, Pearl River, New York, USA., Aggarwal S; Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA., Bergman A; Pfizer Worldwide Research, Development and Medical, Pfizer Inc, Cambridge, Massachusetts, USA., Zhu T; Pfizer Worldwide Research, Development and Medical, Pfizer Inc, Cambridge, Massachusetts, USA., Hackman F; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK., Sathish JG; Drug Safety Unit, Pfizer Inc, Pearl River, New York, USA., Updyke L; Drug Safety Unit, Pfizer Inc, Cambridge, Massachusetts, USA., Loudon P; Tenpoint Therapeutics, Cambridge, UK., Krishna G; El Camino Health, Mountain View, California, USA., Clevenbergh P; University Hospital Brugmann, Brussels, Belgium., Hernandez-Mora MG; Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain., Cisneros Herreros JM; Hospital Universitario Virgen Del Rocio, Sevilla, Spain., Albertson TE; UC Davis Medical Center, Sacramento, California, USA., Dougan M; Massachusetts General Hospital, Boston, Massachusetts, USA., Thacker A; Regional One Health, Memphis, Tennessee, USA., Baniecki ML; Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA., Soares H; Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA., Whitlock M; Early Clinical Development, Pfizer Inc, Cambridge, UK., Nucci G; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK., Menon S; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK., Anderson AS; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK., Binks M; Pfizer Worldwide Research, Development and Medical, Pfizer Ltd, Cambridge, UK. |
| Source: | Open forum infectious diseases [Open Forum Infect Dis] 2023 Jul 10; Vol. 10 (8), pp. ofad355. Date of Electronic Publication: 2023 Jul 10 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Published by Oxford University Press on behalf of the Infectious Diseases Society of America Country of Publication: United States NLM ID: 101637045 Publication Model: eCollection Cited Medium: Print ISSN: 2328-8957 (Print) Linking ISSN: 23288957 NLM ISO Abbreviation: Open Forum Infect Dis Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2328-8957 |
|---|---|
| DOI: | 10.1093/ofid/ofad355 |
